COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study.

Int J Chron Obstruct Pulmon Dis · 2013 · PMC3607534 · PMID 23658479

Europe PMC DOI

hedged sentence

0.5700

closest p · 11.4× alpha

0.5700

boldest claim

The sentences

did not reach statistical significanceP = 0.57not close (p > 0.1)

Time to first COPD exacerbation was slightly longer in the CVT-R group compared to the other treatment groups, although it did not reach statistical significance (CVT-R versus CVT-MDI, P = 0.57; CVT-R versus I + A, P = 0.22).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.